Treatment of moderate to severe hidradenitis suppurativa

Annals of Internal Medicine

Volumn 159, Issue 1, 2013, Pages 72-

  Prasad, Vinay ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

CONFLICT OF INTEREST; DISEASE SEVERITY; HUMAN; LANGUAGE; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; SUPPURATIVE HIDRADENITIS; TREATMENT OUTCOME; DRUG ANTAGONISM; FEMALE; MALE; NOTE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879595601     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-1-201307020-00015     Document Type: Letter

References (5)

1. Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157:846-55. [PMID: 23247938]
2. Krumholz HM. Documenting the methods history: would it improve the interpretability of studies? [Editorial]. Circ Cardiovasc Qual Outcomes. 2012;5:418-9. [PMID: 22811497]
3. ClinicalTrials. gov. Changes to NCT00918255 on 2011_05_07. Accessed at http:// clinicaltrials.gov/archive/NCT00918255/2011_05_07/changes on 23 December 2012.
4. ClinicalTrials. gov. Changes to NCT00918255 on 2009_11_12. Accessed at http:// clinicaltrials.gov/archive/NCT00918255/2009_11_12/changes on 23 December 2012.
5. Ioannidis JP. The importance of potential studies that have not existed and registration of observational data sets. JAMA. 2012;308:575-6. [PMID: 22871867]